About
Deverra Therapeutics is a clinical stage biotechnology company dedicated to the development of allogeneic, off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. The company has an exclusive license to a proprietary stem cell expansion and directed-differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and data from 5 clinical trials. This platform can be used to generate a range of unmodified and modified immune cells to treat patients with cancer and infectious diseases.
- Seattle, United States of America
- Legal Name: Deverra Therapeutics, INC.
- Company ID:
- Year Founded: 2020
- Industry: Biotechnology
- Website: https://www.deverratx.com/
- SEC Filings
Highlights
$59.8M
CF Valuation
$992.9K
Total Raised
$1.7M
Revenue
12
Employees
Indicators
Profit Margin
99.7%
(99.7%)
2022: 0%
Current Ratio
0.99
(52.3%)
2022: 0.65
